NEW YORK — Proteomics International Laboratories said on Thursday that it has completed the transfer of the technology underlying its PromarkerD test for diabetic kidney disease to Irish clinical diagnostics firm Atturos.
According to Proteomics International, Atturos will make the mass spectrometry-based laboratory developed test available to licensing partners in Europe. Separately, Proteomics International announced today a deal with Patia Europe to launch the test in Spain as a laboratory-developed test through Atturos.
About a year ago, Proteomics International licensed the test to Patia BioPharma, the parent firm of Patia Europe, for commercialization in Mexico. As part of the deal with Patia Europe, Proteomics International will receive royalties of an undisclosed amount for two years.
"We are excited to be able to offer the test in Europe for the first time, and are working hard to give patients around the world the opportunity to know their diabetic kidney disease status," Proteomics International Managing Director Richard Lipscombe said in a statement.
PromarketD uses mass spec to measure blood-based proteins to predict type 2 diabetes patients' risk of developing diabetic kidney disease. Perth, Australia-based Proteomics International launched an immunoassay version of the test in late 2018.